References
1. Engeler, D.S., et al., The 2013 EAU guidelines on chronic
pelvic pain: is management of chronic pelvic pain a habit, a philosophy,
or a science? 10 years of development. Eur Urol, 2013. 64 (3):
p. 431-9.
2. Hanno, P.M., et al., Diagnosis and treatment of interstitial
cystitis/bladder pain syndrome: AUA guideline amendment. J Urol, 2015.193 (5): p. 1545-53.
3. Rudick, C.N., et al., Mast cell-derived histamine mediates
cystitis pain. PLoS One, 2008. 3 (5): p. e2096.
4. Lewis, S.A., Everything you wanted to know about bladder
epithelium but were afraid to ask. Am J Physiol Renal Physiol, 2000.278 : p. F867-F874.
5. Hauser, P.J., et al., Abnormal expression of differentiation
related proteins and proteoglycan core proteins in the urothelium of
patients with interstitial cystitis. J Urol, 2008. 179 (2): p.
764-9.
6. Hurst, R.E., R.M. Moldwin, and S.G. Mulholland, Bladder defense
molecules, urothelial differentiation, urinary biomarkers, and
interstitial cystitis. Urology, 2007. 69 (4 Suppl): p. 17-23.
7. Hurst, R.E., et al., Functional and structural characteristics
of the glycosaminoglycans of the bladder luminal surface. J Urol, 1987.138 (2): p. 433-7.
8. Rozenberg, B.B., et al., Improving the barrier function of
damaged cultured urothelium using chondroitin sulfate. Neurourol
Urodyn, 2020. 39 (2): p. 558-564.
9. Janssen, D.A., et al., The distribution and function of
chondroitin sulfate and other sulfated glycosaminoglycans in the human
bladder and their contribution to the protective bladder barrier. J
Urol, 2013. 189 (1): p. 336-42.
10. Hurst, R.E., et al., In the absence of overt urothelial
damage, chondroitinase ABC digestion of the GAG layer increases bladder
permeability in ovariectomized female rats. Am J Physiol Renal Physiol,
2016. 310 (10): p. F1074-80.
11. Offiah, I., et al., Manipulating the extracellular matrix: an
animal model of the bladder pain syndrome. Pain, 2017. 158 (1):
p. 161-170.
12. Fraser, M., et al., A surgical model of composite cystoplasty
with cultured urothelial cells: a controlled study of gross outcome and
urothelial phenotype. BJU Int, 2004. 93 : p. 609-616.
13. Lavelle, J.P., Bladder permeability barrier: recovery from
selective injury of surface epithelial cells. Am J Physiol Renal
Physiol, 2002. 283 : p. F242-F253.
14. Frömter, E., Route of passive ion permeation in epithelia.Nature New Biology, 1972. 235 : p. 9-13.
15. Kyker, K.D., J. Coffman, and R.E. Hurst, Exogenous
glycosaminoglycans coat damaged bladder surfaces in experimentally
damaged mouse bladder. BMC Urol, 2005. 5 : p. 4.
16. Hauser, P.J., et al., Restoring barrier function to acid
damaged bladder by intravesical chondroitin sulfate. J Urol, 2009.182 (5): p. 2477-82.
17. De Vita, D., H. Antell, and S. Giordano, Effectiveness of
intravesical hyaluronic acid with or without chondroitin sulfate for
recurrent bacterial cystitis in adult women: a meta-analysis. Int
Urogynecol J, 2013. 24 (4): p. 545-52.
18. Lai, M.C., Y.C. Kuo, and H.C. Kuo, Intravesical hyaluronic
acid for interstitial cystitis/painful bladder syndrome: a comparative
randomized assessment of different regimens. Int J Urol, 2013.20 (2): p. 203-7.
19. Rooney, P., et al., Effect of Glycosaminoglycan Replacement on
Markers of Interstitial Cystitis In Vitro. Frontiers in pharmacology,
2020. 11 : p. 575043-575043.
20. Stellavato, A., et al., Hyaluronic acid and chondroitin
sulfate, alone or in combination, efficiently counteract induced bladder
cell damage and inflammation. PLoS One, 2019. 14 (6): p.
e0218475.
21. Madersbacher, H., A. van Ophoven, and P.E. van Kerrebroeck,GAG layer replenishment therapy for chronic forms of cystitis with
intravesical glycosaminoglycans–a review. Neurourol Urodyn, 2013.32 (1): p. 9-18.
22. Gulpinar, O., et al., Clinical comparison of intravesical
hyaluronic acid and chondroitin sulfate therapies in the treatment of
bladder pain syndrome/interstitial cystitis. Neurourol Urodyn, 2018.37 (1): p. 257-262.